# US 2025/0093351 A1 · Materials and methods for evaluating and treating neuromyelitis optica (nmo)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0093351 A1
- Document ID: US20250093351A1
- Status: Published application
- Kind: A1
- Application number: 18/966,342
- Filed: 2024-12-03
- Published: 2025-03-20
- Earliest claimed: 2008-10-10
- Assignees: Mayo Foundation for Medical Education and Research
- Applicants: Mayo Foundation for Medical Education and Research
- Inventors: Vanda A. Lennon; Sean J. Pittock; Shannon Hinson
- Web page: https://patentgrep.com/patent/US20250093351A1

## CPC

- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- G01N 2333/705: Assays involving receptors, cell surface antigens or cell surface determinants
- G01N 2800/285: Demyelinating diseases; Multipel sclerosis
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides prognostic methods for evaluating the severity of NMO and NMO-associated diseases as well as methods of treating NMO and NMO-associated diseases.

## Claims

### Claim 1

A method of treating an individual that has a disorder related to AQP4 autoimmunity, said method comprising administering an anti-C5 antibody to an individual identified as being serologically positive for aquaporin-4 (AQP4)-IgG autoantibody.

### Claim 2 (depends on 1)

The method of claim 1, wherein said disorder related to AQP4 autoimmunity is a neurological disorder.

### Claim 3 (depends on 2)

The method of claim 2, wherein said neurological disorder is neuromyelitis optica (NMO) or an NMO-associated disease.

### Claim 4 (depends on 1)

The method of claim 1, wherein said disorder related to AQP4 autoimmunity is a connective tissue disorder.

### Claim 5 (depends on 4)

The method of claim 4, wherein said connective tissue disorder is Lupus or Sjogrens syndrome.

### Claim 6 (depends on 1)

The method of claim 1, wherein said disorder related to AQP4 autoimmunity is a cancer.

### Claim 7 (depends on 6)

The method of claim 6, wherein said cancer is breast cancer.

### Claim 8 (depends on 1)

The method of claim 1, wherein said anti-C5 antibody is administered orally.

### Claim 9 (depends on 11)

The method of claim 11, further comprising administering a glutamate receptor antagonist.

### Claim 10 (depends on 9)

The method of claim 9, wherein said glutamate receptor antagonist is selected from the group consisting of 1-amino-3,5-dimethyl-adamantane, 1-aminoadamantane, (+)-3-methoxy-17-methyl-(9α,13α,14α)-morphinan, 17-methyl-9a,13a, 14a-morphinan-3-ol, 2-(2-chlorophenyl)-2-methylamino-cyclohexan-1-one, 1-(1-phenylcyclohexyl)piperidine, (±)cis-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl) cyclohexanol hydrochloride, and 6-(Dimethylamino)-4,4-diphenylheptan-3-one.

### Claim 11 (depends on 10)

The method of claim 10, wherein said glutamate receptor antagonist is 1-amino-3,5-dimethyl-adamantane, 1-aminoadamantane.

### Claim 12 (depends on 1)

The method of claim 1, further comprising monitoring the individual for a decrease in the severity of said disorder related to AQP4 autoimmunity.

### Claim 13

A method of treating an individual that has a disorder related to AQP4 autoimmunity, said method comprising:
identifying an individual that is serologically positive for aquaporin-4 (AQP4)-IgG autoantibody; and
administering an anti-C5 antibody to the individual.
